A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

NCT02819271 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure

Interventions

DRUG: CXL-1427 Ascending Dose
OTHER: Placebo
DRUG: CXL-1427 Descending Dose

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]